Pioneering regenerative med scientist Laura Niklason takes her company public in the latest big SPAC deal. And that gives her a shot at making biotech history
Laura Niklason left a prominent position at Yale last fall so she could take charge of her regenerative med biotech at a critical point in its 17-year history.
Celebrated by Time and Fortune, heralded as a leader in the long-running regenerative med technology story in tissue engineering, with roots in the field that go back to her days as a postdoc in Bob Langer’s storied lab at MIT, the scientific founder of Humacyte made a career switch that put her in charge of a company with 130 staffers and ongoing late-stage programs that could put them on the threshold of commercialization.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.